Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Assets: 2015-2025

Historic Other Non-Current Assets for Spyre Therapeutics (SYRE) over the last 9 years, with Mar 2025 value amounting to $10,000.

  • Spyre Therapeutics' Other Non-Current Assets fell 96.87% to $10,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $10,000, marking a year-over-year decrease of 96.87%. This contributed to the annual value of $10,000 for FY2024, which is 96.89% down from last year.
  • According to the latest figures from Q1 2025, Spyre Therapeutics' Other Non-Current Assets is $10,000, which was down 0.00% from $10,000 recorded in Q4 2024.
  • Spyre Therapeutics' Other Non-Current Assets' 5-year high stood at $1.8 million during Q2 2021, with a 5-year trough of $10,000 in Q3 2024.
  • In the last 3 years, Spyre Therapeutics' Other Non-Current Assets had a median value of $321,000 in 2024 and averaged $547,333.
  • In the last 5 years, Spyre Therapeutics' Other Non-Current Assets grew by 23.07% in 2021 and then plummeted by 99.23% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Other Non-Current Assets stood at $1.8 million in 2021, then dropped by 15.51% to $1.6 million in 2022, then crashed by 79.27% to $322,000 in 2023, then tumbled by 96.89% to $10,000 in 2024, then crashed by 96.87% to $10,000 in 2025.
  • Its last three reported values are $10,000 in Q1 2025, $10,000 for Q4 2024, and $10,000 during Q3 2024.